Wells Fargo’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Wells Fargo’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2	Closed	-$36	–	7841
2023 Q4	$36	Buy	2 +1	+100%	+$16	﹤0.01%	7027
2023 Q3	$29	Buy	+1	New	+$34	﹤0.01%	7092
2023 Q2	–	Hold	0	–	–	–	7470
2023 Q1	–	Hold	0	–	–	–	7386
2022 Q4	–	Hold	0	–	–	–	7342
2022 Q3	–	Hold	0	–	–	–	7937
2022 Q2	–	Hold	0	–	–	–	7981
2022 Q1	–	Hold	0	–	–	–	8294
2021 Q4	–	Hold	0	–	–	–	8204
2021 Q3	–	Hold	0	–	–	–	7847
2021 Q2	–	Hold	0	–	–	–	7787
2021 Q1	–	Hold	0	–	–	–	6299
2020 Q4	–	Hold	0	–	–	–	7313

Wells Fargo's PBLA Position: Q1 2024 in Review

Wells Fargo sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 2 shares — an estimated $36 sold.

Wells Fargo first reported a position in PBLA in Q3 2023 and held it in 2 quarters. The position peaked at $36 in Q4 2023. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

Wells Fargo reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Wells Fargo sold 2 Panbela Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $36.
Wells Fargo first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Wells Fargo's Panbela Therapeutics, Inc. Common Stock position peaked at $36 in Q4 2023.
0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.